Navigation Links
China-Biotics, Inc. Reports First Quarter 2009 Financial Results
Date:8/14/2008

rded in the first quarter of 2009 related to the change in the fair value of the $25 million convertible notes issued in December 2007.

Net income for the first quarter of the 2009 fiscal year was $3.2 million. Excluding the $1.2 million loss on the revaluation of the convertible notes, net income was $4.5 million, up from $3.5 million in the same quarter of the prior year.

Diluted earnings per share were $0.23 calculated on a weighted average basis, compared with $0.21 per diluted share in the first quarter of fiscal 2008. The calculation of diluted earnings per share for the first quarter of 2008 assumes full conversion of the convertible notes and thus excludes the loss from the change in fair value of the notes.

Financial Condition

As of June 30, 2008, the Company had cash and cash equivalents of $66.2 million and working capital of $50.7 million. The increase in cash resulted in part from the private placement of $25 million of the Company's convertible notes in December 2007. In the first quarter of 2009, China-Biotics generated $8.3 million in cash flow from operations and recorded $7.2 million in capital expenditures related to the construction of the new manufacturing facility. Accounts receivable declined to $10.7 million from $13.2 million on March 31, 2008, and days' sales outstanding for the first quarter of 2009 was 96 days. At June 30, 2008, the Company had stockholders' equity of $48.5 million.

Business Outlook

The Company's new bulk additives production facility remains scheduled to begin production in the Company's fiscal third quarter. As of June 30, 2008, China-Biotics had signed contracts with four business customers to supply those customers with bulk probiotics in powder form that can be added to products such as milk, ice cream, yogurt, baked goods and nutritional supplements.

The Company's retail strategy is also on schedule, with 83 Shining retail outlets open as of June 30, 2008, in Shanghai
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China-Biotics, Inc. Files Application for Nasdaq Listing
3. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
4. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
5. China-Biotics, Inc. to Present at Chinas 3rd Annual Food Safety Technology Forum 2008
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
7. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
8. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
9. China-Biotics, Inc. Completes Foundation for Its New Plant
10. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
11. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... Healthcare , a provider of medical imaging products, has ... posed by the fusing of two large data sets. ... year as it attempts to recover from past financial ... reading methods obtained by PET (positron emission and tomography) ...
... Wis. The technology industry in Dane County saw its ... grew to 510 businesses, according to the 2007 Greater Madison ... & Electric Co. , , Purchase online ... next week, lists technology businesses in 12 industry clusters. They ...
... Wis . - Calling President Bush severely out of ... calling for passage of a bill to lift federal restrictions on ... - the Stem Cell Research Enhancement Act of 2007 - is ... federal funding imposed by Bush in 2001. , ,Doyle urged passage ...
Cached Biology Technology:Directory shows high-tech growth spurt in Dane Co. 2Directory shows high-tech growth spurt in Dane Co. 3Directory shows high-tech growth spurt in Dane Co. 4Doyle joins governors in support of stem cell bill 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... the Wyss Institute for Biologically Inspired Engineering at ... replicates the exceptional strength, toughness, and versatility of ... low-cost, biodegradable, and biocompatible, the new material, called ... products and be used safely in a variety ...
... there,s a native frog rising in the West. With ... Elizabeth Davidson has young children imagining the life cycles and ... and cheering for the underfrog. "Cheery: The true adventures ... by Davidson and brought to life by graphic artist Michael ...
... the weather could be developed, thanks to fresh discoveries about ... tiny algae renew old or damaged cell proteins say their ... in which weather changes quickly. Researchers found that the ... they can adapt to environmental changes, such as a sudden ...
Cached Biology News:Inspired by insect cuticle, Wyss Institute develops material that's tough and strong 2Picture book portrays a 'hoppy' future for endangered frogs 2Picture book portrays a 'hoppy' future for endangered frogs 3